BioCentury
ARTICLE | Clinical News

BritLofex lofexidine: Phase III data

June 23, 2008 7:00 AM UTC

Top-line data from a double-blind, U.S. Phase III trial showed that lofexidine met the primary endpoint of a significant reduction in withdrawal symptoms at day 3 compared with placebo. US WorldMeds s...